

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:)	
)	
Beamer, et al.)	
)	
Application No.: 09/446,415)	
)	
371 Date: July 19, 2000)	EXPRESS MAIL NO. <u>EV 193996668 US</u>
)	
U.S. National Phase of: PCT/US98/13007)	DATE OF MAILING: <u>January 29, 2003</u>
)	
International Filing Date: June 22, 1998)	
)	
For: BACTERICIDAL/PERMEABILITY-)	
INCREASING PROTEIN:)	
CRYSTALLIZATION, X-RAY)	
DIFFRACTION, THREE-)	
DIMENSIONAL STRUCTURE)	
DETERMINATION, RATIONAL)	
DRUG DESIGN AND MOLECULAR)	
MODELING OF RELATED)	
PROTEINS)	
)	
Examiner: A. Marschel, Ph.D.)	
)	
Group Art Unit: 1631)	

COMBINED STATEMENT UNDER 37 C.F.R. §§1.821 and 1.825

Commissioner for Patents
Washington, D.C. 20231


Sir:

In accordance with 37 CFR § 1.825(b), I hereby state that the contents of the attached paper and computer readable copies of the Substitute Sequence Listing submitted in accordance with 37 CFR §§ 1.821(c) and (e), respectively, are the same.

In accordance with 37 CFR §§ 1.825(a), I further state that the disclosure in the Substitute Sequence Listing submitted herewith, is supported in the specification, as the

application was filed as a § 371 National Phase Application on July 19, 2000, and does not include new matter.

Respectfully submitted,

A handwritten signature in cursive script, reading "Michael B. Harlin", written in black ink. The signature is positioned above a horizontal line.

Janet M. McNicholas, Ph.D.

Registration No. 32,918

Michael B. Harlin

Registration No. 43,658

DATED: January 29, 2003

McAndrews, Held & Malloy, Ltd.
500 West Madison Street, Suite 3400
Chicago, Illinois 60661
(312) 775-8000